Esi̇n Aktas-Cetin

Prof. Dr. Esi̇n Aktas-Cetin


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Immunity
Verified
Journal Article
Closed access
Hani HarbHani Harb
Hani Harb
MBMehdi Benamar
Mehdi Benamar
PLPeggy S. Lai
Peggy S. Lai
PCPaola Contini
Paola Contini
JGJason W. Griffith
Jason W. Griffith
TCTalal A. Chatila
Talal A. Chatila



4 April 2017 in Immunological Investigations
Verified
Journal Article
Closed access
FCFulya Cosan
Fulya Cosan
EAEsi̇n Aktas-Cetin
Esi̇n Aktas-Cetin
NANilgun Akdeniz
Nilgun Akdeniz
ZEZeliha Emrence
Zeliha Emrence
ACAyse Cefle
Ayse Cefle
GDGunnur Deniz
Gunnur Deniz
Background: Behçet’s disease (BD) is a rare, chronic autoinflammatory disorder of unknown origin. Natural killer (NK) cells are one of the major immunoregulatory cell groups of the innate immune system, but their role in BD pathogenesis is not well documented. Objectives: We aimed to investigate the role of NK cell subsets and their cytokine secretion and cytotoxic activity in patients with BD. Patients and methods: The study group consisted of BD patients who had only mucocutaneous involvement, and they were compared with healthy subjects. BD patients were divided into two groups according to their frequencies of oral ulcerations. NK cell cytotoxicity was determined using CD107a expression and a CFSE-based cytotoxicity test. Expression of NK cell receptors and surface markers and the intracellular IL-5, IL-10, IL-17, and IFN-γ levels in CD16+ NK cells were assessed by flow cytometry. Results: Although the cytokine secretion pattern was different, no difference was obtained in cytotoxic activity, expression of activatory receptors, or degranulation of NK cells. Conclusion: Increases in NK1/NK2 ratio and CD16+IFN-γ+ NK1 cells might support the idea of a biased IFN-γ dominant immune response in the mucocutaneous involvement of BD pathogenesis. Although the cytokine secretion pattern was different, no difference was obtained in cytotoxic activity, expression of activatory receptors, or degranulation of NK cells.

26 September 2012 in BMC Psychiatry
Verified
Journal Article
Open access
PDF file
TCTuran Cetin
Turan Cetin
SGSinan Guloksuz
Sinan Guloksuz
EAEsi̇n Aktas-Cetin
Esi̇n Aktas-Cetin
SGSema Bilgic Gazioglu
Sema Bilgic Gazioglu
GDGünnur Deniz
Günnur Deniz
JOJim van Os
Jim van Os
Current evidence suggests that high concentrations of pro-inflammatory markers are associated with bipolar disorder characterized by severe impairment during inter-episodic periods, reduced treatment response and persistent subsyndromal symptoms. We tested whether persistent subsyndromal symptoms in euthymic bipolar patients were associated with markers of an ongoing chronic pro-inflammatory process. Forty-five euthymic bipolar patients (22 with subsyndromal symptoms (BD+) and 23 without subsyndromal symptoms (BD-) and 23 well controls (WC) were recruited for assessment of soluble tumor necrosis factor receptor-1 (sTNF-R1), soluble interleukin-6 receptor (sIL-6R) and soluble interleukin-2 receptor (sIL-2R) concentrations. Soluble cytokine receptor concentrations were assessed using enzyme-linked immunosorbent assay. In comparison to WC, sTNF-R1 concentration was higher in both BD- and BD+ (age and sex adjusted standardized β, respectively: β = 0.34, p = 0.012 and β = 0.41, p = 0.003). Similarly, compared to WC, sIL-6R concentration was higher in both BD- and BD+ (age and sex adjusted standardized β, respectively: β = 0.44, p = 0.001 and β = 0.37, p = 0.008). There was no difference between BD- and BD+ in the concentration of either sTNF-R1 or sIL-6R; plasma concentration of sIL-2R was not analyzed as 75% percent of the samples were non-detectable. Although bipolar patients present with a pro-inflammatory shift compared to well controls, subsyndromal symptoms are not associated with additive increasing effects. Longitudinal studies with larger samples are required to clarify the relationship between illness course and inflammatory markers in bipolar disorder.

1 January 2011 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
MEMine Ergüven
Mine Ergüven
ABAyhan Bilir
Ayhan Bilir
NYNuray Yazihan
Nuray Yazihan
EEEzgi Ermis
Ezgi Ermis
ASAkin Sabanci
Akin Sabanci
VAVehbi Alpman
Vehbi Alpman
Glioblastoma (GBM) develops resistance to the advances in chemotherapy leading to poor prognosis and life quality. Consequently, new treatment modalities are needed. Our aims were to investigate the effects of combined noscapine (NOS) and imatinib mesylate (IM) on human GBM in vitro and the role of midkine (MK) in this new combination treatment.